The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy: Pilot study results.
D. R. Gandara
Consultant or Advisory Role - Boehringer Ingelheim; Genentech; Merck
T. A. Van Dyke
No relevant relationships to disclose
Z. Weaver Ohler
No relevant relationships to disclose
T. Li
Consultant or Advisory Role - AstraZeneca; Genentech; Merck
Research Funding - Lilly; OSI Pharmaceuticals
P. Lara
Consultant or Advisory Role - Genentech
Research Funding - Genentech
P. C. Mack
Research Funding - Merck
R. F. Calhoun
No relevant relationships to disclose
R. Gandour-Edwards
No relevant relationships to disclose
K. D. Danenberg
Employment or Leadership Position - Response Genetics
Stock Ownership - Response Genetics (B)
R. de Vere White
No relevant relationships to disclose
N. Goodwin
No relevant relationships to disclose